M
Michael D. Prados
Researcher at University of California, San Francisco
Publications - 466
Citations - 57545
Michael D. Prados is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 107, co-authored 444 publications receiving 51418 citations. Previous affiliations of Michael D. Prados include Harvard University & University of Texas at Austin.
Papers
More filters
Proceedings ArticleDOI
Abstract PO-116: Identifying disparities across race, ethnicity, and gender in pediatric neuro-oncology clinical research - from patient to provider
Emily Marshall,Tom B. Davidson,Jeffrey Stevens,Kristina Cole,Fatema Malbari,Tabitha Cooney,Lance Ballaster,Kaitlin Lehmann,Shannon Robins,Miguel Brown,C. Mark Blackden,Christopher Friedman,Ammar S. Naqvi,J. C. Waller,Jennifer Mason,Jena Lilly,Phillip B. Storm,Adam C. Resnick,Michael D. Prados,Sabine Mueller,Angela J. Waanders,Cassie Kline +21 more
TL;DR: For instance, the authors found that the experiences and feelings of inclusion and treatment of clinical research members within the clinical research environment of pediatric neuro-oncology differ based on self-identified race and gender.
Journal ArticleDOI
Radiation Is an Important Component of Multimodality Therapy for Pediatric Supratentorial Neuroectodermal Tumors
S.M. Daganzo,A. Banerjee,Nalin Gupta,Kathleen R. Lamborn,Michael D. Prados,M.S. Berger,William M. Wara,Daphne A. Haas-Kogan +7 more
TL;DR: Up-front radiotherapy and gross total resection may confer a survival benefit in patients with sPNET and efforts should be made to determine patients most likely to have local failure exclusively or as a first recurrence in order to delay or eliminate cranio-spinal irradiation (CSI).
Journal ArticleDOI
In reference to lamborn et Al. (Neuro-oncology. 2008;10:162-170).
TL;DR: The conclusion of a workshop sponsored by the FDA, American Association for Cancer Research, and American Society of Clinical Oncology evaluating end points for registrational trials of new agents to treat primary brain cancer stated that “the limitations of imaging-based assessment can in part be ameliorated by incorporation of additional clinically observed, neurocognitive, and patient reported outcomes into a composite progression endpoint.
Journal ArticleDOI
NURS-02. Incorporating Nurses and Advanced Practice Providers into Clinical Trial Consortiums; results of a multi-institutional survey from the Pacific Pediatric Neuro-Oncology Consortium (PNOC)
TL;DR: A nursing and APP working group has been established within PNOC in response to the needs-based survey results, and the working group provides a quarterly nursing newsletter, offers education sessions and mentorship opportunities, and participates in multi-disciplinary, disease-specific working groups.